Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)

Gail Vance, Haesook Kim, Gary A. Hicks, Athena M. Cherry, Rodney Higgins, Rachael L. Hulshizer, Martin S. Tallman, Hugo F. Fernandez, Gordon W. Dewald

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We evaluated the efficacy of FISH to detect chromosome anomalies in the evaluation of young (<60 years) patients with AML. Patients were enrolled in E1900, an ECOG clinical trial for AML. The protocol was designed to collect bone marrow or blood for both cytogenetic and FISH studies at study entry (diagnosis). FISH for each patient was performed and utilized eight probe sets to detect t(8;21), t(9;22), t(11;var), t(15;17), inv(16), +8, -5/5q, and -7/7q. We analyzed 237 specimens with complete cytogenetic and FISH results. Results for each specimen were classified by probe set into one of six categories. The concordance rate between cytogenetic and FISH results ranged from 98 to 100% for all probe sets and kappa analysis for concordance had a p-value of <0.0001. The high level of agreement between cytogenetic and FISH results demonstrate the accuracy of a panel of eight FISH probe sets for the detection of significant abnormalities in AML. Data from this investigation support the use of FISH as an adjunct method to increase the yield of useful cytogenetic results in large cooperative trials and demonstrate the potential of FISH as a follow-up study of minimal residual disease in ECOG trials.

Original languageEnglish
Pages (from-to)605-609
Number of pages5
JournalLeukemia Research
Volume31
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Interphase
Cytogenetics
Clinical Trials
Residual Neoplasm
Chromosomes
Bone Marrow

Keywords

  • Acute myeloid leukemia
  • Cytogenetics
  • FISH

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). / Vance, Gail; Kim, Haesook; Hicks, Gary A.; Cherry, Athena M.; Higgins, Rodney; Hulshizer, Rachael L.; Tallman, Martin S.; Fernandez, Hugo F.; Dewald, Gordon W.

In: Leukemia Research, Vol. 31, No. 5, 05.2007, p. 605-609.

Research output: Contribution to journalArticle

Vance, Gail ; Kim, Haesook ; Hicks, Gary A. ; Cherry, Athena M. ; Higgins, Rodney ; Hulshizer, Rachael L. ; Tallman, Martin S. ; Fernandez, Hugo F. ; Dewald, Gordon W. / Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). In: Leukemia Research. 2007 ; Vol. 31, No. 5. pp. 605-609.
@article{5550c3b18e924cb1a06a78ca324979a4,
title = "Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)",
abstract = "We evaluated the efficacy of FISH to detect chromosome anomalies in the evaluation of young (<60 years) patients with AML. Patients were enrolled in E1900, an ECOG clinical trial for AML. The protocol was designed to collect bone marrow or blood for both cytogenetic and FISH studies at study entry (diagnosis). FISH for each patient was performed and utilized eight probe sets to detect t(8;21), t(9;22), t(11;var), t(15;17), inv(16), +8, -5/5q, and -7/7q. We analyzed 237 specimens with complete cytogenetic and FISH results. Results for each specimen were classified by probe set into one of six categories. The concordance rate between cytogenetic and FISH results ranged from 98 to 100{\%} for all probe sets and kappa analysis for concordance had a p-value of <0.0001. The high level of agreement between cytogenetic and FISH results demonstrate the accuracy of a panel of eight FISH probe sets for the detection of significant abnormalities in AML. Data from this investigation support the use of FISH as an adjunct method to increase the yield of useful cytogenetic results in large cooperative trials and demonstrate the potential of FISH as a follow-up study of minimal residual disease in ECOG trials.",
keywords = "Acute myeloid leukemia, Cytogenetics, FISH",
author = "Gail Vance and Haesook Kim and Hicks, {Gary A.} and Cherry, {Athena M.} and Rodney Higgins and Hulshizer, {Rachael L.} and Tallman, {Martin S.} and Fernandez, {Hugo F.} and Dewald, {Gordon W.}",
year = "2007",
month = "5",
doi = "10.1016/j.leukres.2006.07.026",
language = "English",
volume = "31",
pages = "605--609",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)

AU - Vance, Gail

AU - Kim, Haesook

AU - Hicks, Gary A.

AU - Cherry, Athena M.

AU - Higgins, Rodney

AU - Hulshizer, Rachael L.

AU - Tallman, Martin S.

AU - Fernandez, Hugo F.

AU - Dewald, Gordon W.

PY - 2007/5

Y1 - 2007/5

N2 - We evaluated the efficacy of FISH to detect chromosome anomalies in the evaluation of young (<60 years) patients with AML. Patients were enrolled in E1900, an ECOG clinical trial for AML. The protocol was designed to collect bone marrow or blood for both cytogenetic and FISH studies at study entry (diagnosis). FISH for each patient was performed and utilized eight probe sets to detect t(8;21), t(9;22), t(11;var), t(15;17), inv(16), +8, -5/5q, and -7/7q. We analyzed 237 specimens with complete cytogenetic and FISH results. Results for each specimen were classified by probe set into one of six categories. The concordance rate between cytogenetic and FISH results ranged from 98 to 100% for all probe sets and kappa analysis for concordance had a p-value of <0.0001. The high level of agreement between cytogenetic and FISH results demonstrate the accuracy of a panel of eight FISH probe sets for the detection of significant abnormalities in AML. Data from this investigation support the use of FISH as an adjunct method to increase the yield of useful cytogenetic results in large cooperative trials and demonstrate the potential of FISH as a follow-up study of minimal residual disease in ECOG trials.

AB - We evaluated the efficacy of FISH to detect chromosome anomalies in the evaluation of young (<60 years) patients with AML. Patients were enrolled in E1900, an ECOG clinical trial for AML. The protocol was designed to collect bone marrow or blood for both cytogenetic and FISH studies at study entry (diagnosis). FISH for each patient was performed and utilized eight probe sets to detect t(8;21), t(9;22), t(11;var), t(15;17), inv(16), +8, -5/5q, and -7/7q. We analyzed 237 specimens with complete cytogenetic and FISH results. Results for each specimen were classified by probe set into one of six categories. The concordance rate between cytogenetic and FISH results ranged from 98 to 100% for all probe sets and kappa analysis for concordance had a p-value of <0.0001. The high level of agreement between cytogenetic and FISH results demonstrate the accuracy of a panel of eight FISH probe sets for the detection of significant abnormalities in AML. Data from this investigation support the use of FISH as an adjunct method to increase the yield of useful cytogenetic results in large cooperative trials and demonstrate the potential of FISH as a follow-up study of minimal residual disease in ECOG trials.

KW - Acute myeloid leukemia

KW - Cytogenetics

KW - FISH

UR - http://www.scopus.com/inward/record.url?scp=34147121394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147121394&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.07.026

DO - 10.1016/j.leukres.2006.07.026

M3 - Article

VL - 31

SP - 605

EP - 609

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -